Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2019 08:00 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol

Journal of Ocular Pharmacology and Therapeutics Peer-Reviewed Journal Publishes NB2222 Ocular Bioavailability Data LONG BEACH, CA, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald...
April 01, 2019 07:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act

LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
March 25, 2019 08:00 ET | Source: Emerald Bioscience, Inc.

Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments

Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...
March 18, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing

Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing ...
March 12, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues

Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation Changes in Neovascularization...
March 04, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog

Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina LONG BEACH, CA, March 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc....
January 23, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience to Present at the NobleCon XV and 8th Annual Glaucoma 360 New Horizons Forum

LONG BEACH, CA, Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
October 15, 2018 08:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience to Present at BIO Investor Forum

LONG BEACH, CA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
October 08, 2018 08:00 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares

Avtar Dhillon, MD, appointed as Executive Chairman of Nemus LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the...
September 26, 2018 08:00 ET | Source: Nemus Bioscience, Inc.

NEMUS Bioscience to Present at The MicroCap Conference

LONG BEACH, CA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...

Next Page keyboard_arrow_right